Despite being one of the most commonly encountered conditions in primary care and gastroenterology practices, an overwhelming number of patients with irritable bowel syndrome (IBS) remain undiagnosed. Misdiagnosis, misunderstanding, and a lack of patient-centered care alienate patients with IBS who are seeking support, guidance, and treatment. Newly published American College of Gastroenterology guidelines for diagnosing and treating patients with IBS exist but are not routinely implemented, resulting in diagnostic delays. There is a need for strategies to improve diagnostic accuracy, familiarization with efficacious and safe IBS therapies, and patient-centered care, including shared decision-making (SDM), education, and patient-reported outcomes (PROs).
This live CME Outfitters symposium will feature an expert panel discussion crafted with a focus on patients with IBS that provides strategies for obtaining accurate diagnosis, presents new and emerging clinical data on the efficacy and safety of IBS therapies, and details approaches for patient-centered care to achieve optimal outcomes.
At the end of this CME/CE activity, participants should be able to:
Supported by educational grants from AbbVie Inc. and Ironwood Pharmaceuticals, Inc.
Physicians, PAs, nurse practitioners, nurses, and pharmacists specializing in gastroenterology and/or primary care.
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. Chey reports the following financial relationships: Consultant: AbbVie Inc; Alnylam Pharmaceuticals Inc.; Arena Pharmaceuticals, Inc.; Biomerica, Inc.; Covita; Everlywell, Inc.; Gemelli Biotech; IM Health; Ironwood Pharmaceuticals, Inc.; ISOThrive Inc.; Nestle; Phathom Pharmaceuticals; Progenity, Inc.; QOL Medical; RedHill Biopharma Inc.; Salix Pharmaceuticals/Valeant Pharmaceuticals; Takeda Pharmaceuticals U.S.A., Inc.; Urovant Sciences, Inc.; and Vibrant Pharma Inc. Research Support: Biomerica, Inc.; Commonwealth Diagnostics International, Inc.; U.S. Food and Drug Administration (FDA); National Institutes of Health (NIH); QOL Medical; and Salix Pharmaceuticals. Stock Shareholder (directly purchased): Options: Options: GI OnDEMAND; ISOThrive Inc.; and ModifyHealth, LLC. Other: Patents: Digital Manometry; Nutrition Health; and Rectal Expulsion Device
Dr. Chang reports the following financial relationships: Advisory Board: Ardelyx; Arena Pharmaceuticals, Inc.; Cosmo Pharmaceuticals; Immunic Therapeutics; Ironwood Pharmaceuticals, Inc.; Mauna Kea Technologies; and Protagonist Therapeutics Inc. Consultant: Trellus, Inc. Research Support: AnX Robotica; Arena Pharmaceuticals, Inc.; Ironwood Pharmaceuticals, Inc.; and Vanda Pharmaceuticals. Speakers Bureau: AbbVie Inc. Stock Shareholder (ownership interest): ModifyHealth, LLC and Trellus, Inc.
Ms. Ladewski reports the following financial relationships: Advisory Board: Mahana Therapeutics, Inc. and Phathom Pharmaceuticals. Consultant: Ironwood Pharmaceuticals, Inc. and Salix Pharmaceuticals. Speakers Bureau: Salix Pharmaceuticals and Takeda Pharmaceuticals U.S.A., Inc.
The following peer reviewer and CME Outfitters staff report no financial relationships:
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
NOTE: Pharmacist CE Universal Activity Number, Enduring: JA0007185-0000-22-073-H01-P.
Call us at 877.CME.PROS (877.263.7767).